Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIORESAL vs CARISOPRODOL COMPOUND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
FDA-approved: Intrathecal: severe spasticity of cerebral or spinal origin; Oral: spasticity in multiple sclerosis, spinal cord injury. Off-label: Trigeminal neuralgia, essential tremor, chronic hiccups, alcohol withdrawal, stiff-person syndrome, dystonia, gastroesophageal reflux disease, epilepsy, autism, cluster headaches, intractable hiccups, cocaine dependence, Huntington disease, Tourette syndrome, tardive dyskinesia, periodic limb movement disorder, myoclonus, apraxia of eyelid opening, hemifacial spasm, nystagmus, tic disorders, generalized anxiety disorder, insomnia, and chronic hiccup.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Hepatic metabolism via deamination (minor pathway); primarily excreted unchanged in urine (70-80% as parent drug, 15% as metabolites).
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
~30%; primarily bound to albumin.
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution, with higher CNS penetration when administered intrathecally.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Oral: 70-80% (first-pass effect minimal); intrathecal: nearly 100% due to direct CSF administration.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
GFR >60 m L/min: no adjustment; GFR 30-60: reduce dose by 25-50%; GFR <30: avoid or reduce by 75%; hemodialysis: supplement dose after dialysis.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Oral: 2.5 mg 4 times daily initially, increase by 2.5-5 mg every 3 days to max 40 mg/day (2-7 years) or 60 mg/day (8-15 years). Intrathecal: test dose 25-50 mcg; maintenance 100-1000 mcg/day.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Start at 5 mg twice daily; increase slowly due to increased CNS sensitivity; monitor for sedation and confusion.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Abrupt discontinuation of intrathecal baclofen may result in life-threatening withdrawal reactions (high fever, altered mental status, severe spasticity, rhabdomyolysis, autonomic dysfunction).
None
Abrupt discontinuation: may cause withdrawal symptoms (hallucinations, seizures, hyperthermia, rebound spasticity). Sedation: may impair ability to drive or operate machinery. Renal impairment: dose adjustment required. Avoid concomitant use with CNS depressants (alcohol, benzodiazepines). Caution in stroke patients, respiratory depression, psychiatric disorders, epilepsy, and pregnancy.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Absolute: Hypersensitivity to baclofen or any component; concomitant use of oral baclofen and intrathecal baclofen; intrathecal use contraindicated in patients with IV access device infection, spinal canal obstruction, or bleeding diathesis. Relative: Renal impairment, hepatic impairment, respiratory insufficiency, seizure disorder, history of autonomic dysreflexia, pregnancy, and lactation.
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
No specific food interactions, but take with or without food consistently to avoid variable absorption.
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia, and withdrawal symptoms (irritability, tremors) in neonates. Use only if benefit outweighs risk.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Lioresal (baclofen) is excreted into human breast milk in low concentrations; M/P ratio is approximately 0.4-0.7. No adverse effects reported in nursing infants. Caution advised, especially in preterm infants or those with renal impairment.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Dose should be titrated to lowest effective dose, with close monitoring for efficacy and toxicity. No specific dose adjustment guidelines; individualize based on clinical response.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Titrate slowly to avoid sedation and muscle weakness; monitor for withdrawal signs after abrupt discontinuation (e.g., spasticity rebound, hyperpyrexia, seizures). Intrathecal pump requires specialist management.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
Take exactly as prescribed; do not suddenly stop taking this medication.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Report any unusual muscle weakness, confusion, or difficulty breathing.,Keep medication in original container away from moisture and heat.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIORESAL vs CARISOPRODOL COMPOUND, answered by our medical review team.
LIORESAL is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.. CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIORESAL and CARISOPRODOL COMPOUND depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIORESAL is: Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.. The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIORESAL and CARISOPRODOL COMPOUND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIORESAL is classified as Category C. First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.